<DOC>
	<DOCNO>NCT00962026</DOCNO>
	<brief_summary>This study do see investigational drug call rilonacept safe use patient type 1 diabetes , slow loss body 's ability secrete insulin patient still able make small amount insulin .</brief_summary>
	<brief_title>Rilonacept Diabetes Mellitus Type 1 : Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Within 5 year diagnosis type 1 diabetes Between age 16 45 year Have least one diabetesrelated autoantibody present Have mean Cpeptide level &gt; 0.2 nmol/L mixed meal tolerance test Be take insulin Complete write informed consent Taking inhaled oral steroid ( example Advair , Orapred ) Have active infection Have serologic evidence HIV , Hepatitis C , Hepatitis C , tuberculosis Have ongoing use medication know affect glucose tolerance Have live vaccine 90 day prior , study Taking experimental medication within past 28 day Have prior treatment rilonacept Have complicate medical issue abnormal clinical laboratory blood count result interfere study conduct ; history malignancy Pregnant lactate female Males female unwilling use acceptable method contraception duration study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Interleukin 1</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>Rilonacept</keyword>
	<keyword>Arcalyst</keyword>
</DOC>